# EDGAR Filing Document

**Accession Number:** 0001715925
**File Stem:** 0001193125-25-279233
**Filing Date:** 2025-11
**Character Count:** 4139
**Document Hash:** 7612cef3cd8605f89c2baf3cf3cf30ac
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-279233.hdr.sgml**: 20251113

**ACCESSION NUMBER**: 0001193125-25-279233

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251113

**FILED AS OF DATE**: 20251113

**DATE AS OF CHANGE**: 20251113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** MindWalk Holdings Corp.
- **CENTRAL INDEX KEY:** 0001715925
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39530
- **FILM NUMBER:** 251475952

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 3204-4464 MARKHAM STREET
- **CITY:** VICTORIA
- **NON US STATE TERRITORY:** BRITISH COLUMBIA
- **PROVINCE COUNTRY:** A1
- **BUSINESS PHONE:** 6048060626

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 3204-4464 MARKHAM STREET
- **CITY:** VICTORIA
- **NON US STATE TERRITORY:** BRITISH COLUMBIA
- **PROVINCE COUNTRY:** A1

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ImmunoPrecise Antibodies Ltd.
- **DATE OF NAME CHANGE:** 20170830

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**Form 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16** 

**OF THE SECURITIES EXCHANGE ACT OF 1934** 

For the month of **<u>November, 2025</u>**.

Commission File Number: **<u>001-39530</u>**

**<u>MindWalk Holdings Corp.</u>** 

**3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8**

(Address of principal executive office)

------

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit**<br>| &nbsp;&nbsp;&nbsp;**Description**<br>|
| &nbsp;&nbsp;99.1<br>| [<u>Press Release dated November 13, 2025</u>](hyft-ex99_1.htm) |

---

------

**<u>SIGNATURES</u>** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MINDWALK HOLDINGS CORP.** | **MINDWALK HOLDINGS CORP.** |
| Date: November 13, 2025 |  |  |
|  | By: | /s/ Jennifer Bath<br>|
|  | Name: | Jennifer Bath |
|  | Title: | President and Chief Executive Officer |

---

------

## Exhibit 99.1

99.1 **MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025** 

AUSTIN, Texas--(BUSINESS WIRE) - MindWalk Holdings Corp.™ ("MindWalk," "Company," "we" or "us") (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM.

The AI Drug Discovery & Development Summit is a premier event that brings together industry leaders, researchers, and innovators to explore how artificial intelligence is reshaping drug discovery pipelines and accelerating therapeutic development. Dr. Van Hyfte will share insights on how MindWalk's HYFT®-powered LensAi™ platform is unlocking new opportunities to index, connect, and continuously update biological knowledge at scale—redefining how the industry approaches discovery and development.

"We're pleased to see Dr. Van Hyfte representing MindWalk's vision for Bio-Native AI and Deep Data internationally," said Dr. Jennifer Bath, CEO of MindWalk. "His work exemplifies how scientific depth and data-driven design can come together to advance precision discovery."

For more information on the event, visit the official website: <u>AI Drug Discovery & Development Summit 2025</u> 

**About MindWalk** 

**Investor Contact** 

Louie Toma, CPA, CFA

Managing Director, CoreIR

investors@mindwalkAI.com

Source: MindWalk Holdings Corp.

------